{"id":5727,"date":"2023-10-11T18:01:38","date_gmt":"2023-10-11T18:01:38","guid":{"rendered":"https:\/\/blogs.sld.cu\/oserranob\/?p=5727"},"modified":"2023-10-11T18:01:38","modified_gmt":"2023-10-11T18:01:38","slug":"omicas-en-oncologia-diagnostico-terapias-biomarcadores","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2023\/10\/11\/omicas-en-oncologia-diagnostico-terapias-biomarcadores\/","title":{"rendered":"\u00d3micas en oncolog\u00eda: diagn\u00f3stico, terapias, biomarcadores"},"content":{"rendered":"<p>&#8211; <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-first-marketing-authorization-dna-test-assess-predisposition-dozens-cancer-types\">FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types<\/a>. September 29, 2023.<br \/>\n&#8211; <a href=\"https:\/\/www.cell.com\/cell-reports\/fulltext\/S2211-1247(23)00989-0\">Genome-guided discovery of cancer therapeutic targets<\/a>. Cell Reports, 2023;42(8):112978.<br \/>\n&#8211; <a href=\"https:\/\/www.ijp-online.com\/text.asp?2023\/55\/4\/213\/385498\">Genomic biomarkers: Unveiling the potential for precise cancer therapy response<\/a>. Indian J Pharmacol, 2023;55:213-5.<br \/>\n&#8211; <a href=\"https:\/\/www.science.org\/doi\/full\/10.1126\/scitranslmed.adh4181\">Identifying predictors of glioma evolution from longitudinal sequencing<\/a>. Science Translational Medicine, 2023;15(716).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types. September 29, 2023. &#8211; Genome-guided discovery of cancer therapeutic targets. Cell Reports, 2023;42(8):112978. &#8211; Genomic biomarkers: Unveiling the potential for precise cancer therapy response. Indian J Pharmacol, 2023;55:213-5. &#8211; Identifying predictors of glioma evolution from longitudinal sequencing. [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[11,15,19,23,32],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/5727"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=5727"}],"version-history":[{"count":1,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/5727\/revisions"}],"predecessor-version":[{"id":5728,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/5727\/revisions\/5728"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=5727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=5727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=5727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}